Lorino A M, Lofaso F, Drogou I, Abi-Nader F, Dahan E, Coste A, Lorino H
INSERM U 296 et Service de Physiologie, Explorations Fonctionnelles, Hôpital Henri Mondor, Créteil, France.
Chest. 1998 Jul;114(1):166-70. doi: 10.1378/chest.114.1.166.
The goal of this study was to compare the effectiveness of three treatments aiming to reduce nasal airflow resistance (NR): an external nasal strip device (Respir+), an internal nasal mechanical dilator (Nozovent), and a topical decongestant (Pernazène). NR was estimated by active posterior rhinometry at both a 0.5 L/s flow (NRF) and a 1 cm H2O pressure (NRP), under four conditions: in the basal state, with Respir+, with Nozovent, and after treatment with Pernazène. The efficacy of each treatment was assessed by the percentage changes in NRF and NRP (%NRF and %NRP, respectively). The study was performed in 15 healthy subjects. The efficacy of the treatments was significantly different, depending on whether it was evaluated by NRF or by NRP (p<0.02), with %NRF and %NRP values, respectively, equal to the following: 88+/-20% and 91+/-14% with Respir+, 58+/-17% and 70+/-13% with Nozovent, and 55+/-29% and 69+/-22% with Pernazène. NRF remained unchanged with Respir+, whereas it significantly decreased with Nozovent and Pernazène (p<0.0001). No significant difference was observed between the effects of the two latter treatments. These results demonstrate that Nozovent, which involves no risk of side effects or drug interactions, is an effective treatment to improve nasal breathing. Nozovent might therefore be recommended as an alternative to topical decongestants, for certain subjects presenting with nasal obstruction.
本研究的目的是比较三种旨在降低鼻气流阻力(NR)的治疗方法的有效性:一种外部鼻贴装置(Respir+)、一种内部鼻机械扩张器(Nozovent)和一种局部减充血剂(Pernazène)。通过主动后鼻测量法在0.5 L/s流量(NRF)和1 cm H2O压力(NRP)下,在四种条件下估计NR:基础状态、使用Respir+时、使用Nozovent时以及使用Pernazène治疗后。每种治疗方法的疗效通过NRF和NRP的百分比变化(分别为%NRF和%NRP)进行评估。该研究在15名健康受试者中进行。根据评估是通过NRF还是NRP进行,治疗方法的疗效存在显著差异(p<0.02),%NRF和%NRP值分别如下:使用Respir+时为88±20%和91±14%,使用Nozovent时为58±17%和70±13%,使用Pernazène时为55±29%和69±22%。使用Respir+时NRF保持不变,而使用Nozovent和Pernazène时NRF显著降低(p<0.0001)。后两种治疗方法的效果之间未观察到显著差异。这些结果表明,Nozovent不存在副作用或药物相互作用的风险,是改善鼻呼吸的有效治疗方法。因此,对于某些有鼻塞症状的受试者,Nozovent可能被推荐作为局部减充血剂的替代品。